摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(4-氯-1H-吡唑-1-基)乙酸 | 32089-46-6

中文名称
(4-氯-1H-吡唑-1-基)乙酸
中文别名
——
英文名称
2-(4-chloro-1H-pyrazol-1-yl)acetic acid
英文别名
(4-Chloro-pyrazol-1-yl)-acetic acid;2-(4-chloropyrazol-1-yl)acetic acid
(4-氯-1H-吡唑-1-基)乙酸化学式
CAS
32089-46-6
化学式
C5H5ClN2O2
mdl
MFCD00036053
分子量
160.56
InChiKey
KPXIVTIAZUNIOR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    338.9±22.0 °C(Predicted)
  • 密度:
    1.54±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.6
  • 重原子数:
    10
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    55.1
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 危险等级:
    IRRITANT
  • 危险品标志:
    Xi
  • 海关编码:
    2933199090
  • 危险性防范说明:
    P261,P280,P301+P312,P305+P351+P338
  • 危险性描述:
    H302+H312+H332,H315,H319,H335

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    ANTAGONISTS OF CHEMOKINE RECEPTORS
    摘要:
    提供了作为CCR1受体的强效拮抗剂的化合物,并具有体内抗炎活性。这些化合物通常是芳基哌嗪衍生物,可用于制药组合物、治疗CCR1介导疾病的方法,以及作为竞争性CCR1拮抗剂鉴定的控制物。
    公开号:
    US20140057937A1
点击查看最新优质反应信息

文献信息

  • [EN] BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION<br/>[FR] COMPOSÉS BICYCLIQUES DESTINÉS À LA RÉDUCTION DE LA PRODUCTION DE BÉTA-AMYLOÏDES
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2010083141A1
    公开(公告)日:2010-07-22
    The present disclosure provides a series of compounds of the formula (I) which reduce β-amyloid peptide (β-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by β-amyloid peptide (β-AP) production, wherein A is a five- or six-membered heteroaromatic ring containing from one to three heteroatoms independently selected from nitrogen, oxygen, and sulfur; B is selected from phenyl and pyridinyl, D is selected from (II) E is selected from Ci-ealkyl, d-ecycloalkyl, benzyl, phenyl, and a five- to six- membered heteroaromatic ring containing one or two nitrogen atoms.
    本公开提供了一系列化合物,其具有式(I),能够减少β-淀粉样肽(β-AP)的产生,并可用于治疗阿尔茨海默病及其他受β-淀粉样肽(β-AP)产生影响的病症。其中,A为含有一至三个独立选自氮、氧和硫的杂原子的五元或六元杂芳香环;B选自苯基和吡啶基;D选自(II);E选自C1-6烷基、C3-6环烷基、苄基、苯基以及含有一或两个氮原子的五元至六元杂芳香环。
  • AROMATIC 5-MEMBERED HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY
    申请人:Shionogi & Co., Ltd.
    公开号:US20150038483A1
    公开(公告)日:2015-02-05
    The present invention is related to a compound represented by formula (I) wherein R 1 is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted aromatic carbocyclyl, or the like; X is —N(R 3 )—, —O—, or —S—; Y is ═C(R 4 )—, or ═N—; Z is —N(R 7 )—, —O—, or —S—; R 2 is substituted or unsubstituted alkyloxy, or the like, or a group represented by the following formula: —(CR 2a R 2b ) n —R 2c , wherein R 2a is each independently a hydrogen atom, halogen, or the like; R 2b is each independently a hydrogen atom, halogen, or the like; R 2a and R 2b which are attached to the same carbon atom may be taken together to form oxo, a substituted or unsubstituted non-aromatic carbocycle, or the like; two of R 2a which are attached to the adjacent carbon atoms and/or two of R 2b which are attached to the adjacent carbon atoms may be taken together to form a bond; R 2c is substituted or unsubstituted aromatic carbocyclyl, or the like; n is an integer from 1 to 3; R 3 and R 7 are each independently a hydrogen atom, substituted or unsubstituted alkyl, or the like; R 4 and R 5 are each independently a hydrogen atom, halogen, substituted or unsubstituted alkyl, or the like; R 6 is a hydrogen atom, halogen, substituted or unsubstituted alkyl, or the like, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof.
    本发明涉及一种由式(I)表示的化合物,其中R1是氢原子,取代或未取代的烷基,取代或未取代的芳香环烷基等;X是—N(R3)—,—O—或—S—;Y是═C(R4)—或═N—;Z是—N(R7)—,—O—或—S—;R2是取代或未取代的烷氧基等,或以下式表示的基团:—(CR2aR2b)n—R2c,其中R2a分别是氢原子,卤素等;R2b分别是氢原子,卤素等;附在同一碳原子上的R2a和R2b可以共同形成氧化物,取代或未取代的非芳香环烷基等;附在相邻碳原子上的两个R2a和/或附在相邻碳原子上的两个R2b可以共同形成键;R2c是取代或未取代的芳香环烷基等;n是1到3的整数;R3和R7分别是氢原子,取代或未取代的烷基等;R4和R5分别是氢原子,卤素,取代或未取代的烷基等;R6是氢原子,卤素,取代或未取代的烷基等,或其药学上可接受的盐,或包含其的药物组合物。
  • Coumarins containing sulphonylamino groups
    申请人:Bayer Aktiengesellschaft
    公开号:US04069228A1
    公开(公告)日:1978-01-17
    Coumarins of the formula ##STR1## wherein R denotes an alkyl radical with 1 to 4 C atoms, which is optionally substituted by halogen atoms or a phenyl radical which is optionally substituted by halogen, C.sub.1 -C.sub.4 -alkyl or C.sub.1 -C.sub.4 -alkoxy and R' represents hydrogen, a phenyl radical which is optionally substituted by nitro, C.sub.1 -C.sub.4 alkyl, halogen or C.sub.1 -C.sub.4 -alkoxy, the tetralin-6-yl radical or an aromatic heterocyclic radical which is bonded via C or N and which can contain further substituents, for example C.sub.1 -C.sub.4 -alkyl groups and halogen atoms Are valuable intermediates for the production of dyestuffs and optical brightening agents.
    式为## STR1 ##的香豆素,其中R表示1至4个C原子的烷基基团,该基团可以选择性地由卤素原子或苯基基团取代,该苯基基团可以选择性地由卤素,C.sub.1-C.sub.4-烷基或C.sub.1-C.sub.4-烷氧基取代,R'表示氢,可以选择性地由硝基,C.sub.1-C.sub.4-烷基,卤素或C.sub.1-C.sub.4-烷氧基取代的苯基基团,四氢萘-6-基基团或通过C或N键结合的芳香族杂环基团,该基团可以包含进一步的取代基,例如C.sub.1-C.sub.4-烷基团和卤素原子,是生产染料和光亮剂的有价值的中间体。
  • Bicyclic compounds for the reduction of beta-amyloid production
    申请人:Bristol-Myers Squibb Company
    公开号:US08349880B2
    公开(公告)日:2013-01-08
    The present disclosure provides a series of compounds of the formula (I) which reduce β-amyloid peptide (β-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by β-amyloid peptide (β-AP) production.
    本公开提供了一系列式(I)的化合物,可减少β淀粉样肽(β-AP)的产生,并可用于治疗阿尔茨海默病和其他受β淀粉样肽(β-AP)产生影响的疾病。
  • Antagonists of chemokine receptors
    申请人:ChemoCentryx, Inc.
    公开号:US09181241B2
    公开(公告)日:2015-11-10
    Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    提供了一些化合物,它们作为CCR1受体的有效拮抗剂,并具有体内抗炎活性。这些化合物通常是芳基哌嗪衍生物,并可用于制备药物组合物,用于治疗CCR1介导的疾病的方法,以及作为竞争性CCR1拮抗剂鉴定的控制物。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物

相关功能分类